A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness.

Trial Profile

A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Sponsors Aerial BioPharma
  • Most Recent Events

    • 25 May 2012 Actual patient number (33) added as reported by ClinicalTrials.gov.
    • 25 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 25 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top